Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Ryan Chang's Biography



Ryan Chang, CEO, Steminent Biotherapeutics

Ryan Chang is the CEO of Steminent Biotherapeutics in Taiwan, the leading Phase-2 stage company dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes its proprietary Stemchymal® platform to manufacture standardized stem cell products of the highest quality for research and clinical development in neurodegenerative, liver, and other therapeutic areas.

Ryan has had a diverse management and strategic executions across high tech, manufacturing, and biomedical industries. Prior to Steminent, Ryan was the Asia head of SKF mechatronics business unit, overseeing operations and product lines, and business development. A veteran in microarray development in his earlier career, Ryan felt strongly what biomedical breakthrough could bring to human lives and the society. Regenerative Medicine is emerging to represent next frontier to help suffering patients with complex diseases that haven’t had effective cures today. Ryan was educated in New York University with both MA in Political Economy and MBA. He took an additional MBA training in Technology Management from the renowned National Chengchi University in Taiwan and a series of executive programs in China, Singapore, and India.

Ryan Chang Image

Therapeutic Considerations of Mesenchymal Stromal Cells

Monday, 11 November 2019 at 14:40

Add to Calendar ▼2019-11-11 14:40:002019-11-11 15:40:00Europe/LondonTherapeutic Considerations of Mesenchymal Stromal CellsCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

Mesenchymal Stromal Cells (MSCs), with its unique anti-inflammatory and immunomodulatory functions, have been widely considered as a viable drug agent for many unmet or underserved disease indications. Anyhow challenges remain before we can see more popularized clinical applications. Some critical dimensions include the high level of biological complexities, regulatory requirements, and manufacturing scale-up. This presentation will have an overview of some essential issues to be considered, along with suggested approaches in developing viable clinical use of MSCs. Steminent Biotherapeutics, with its proprietary allogenic stem cell technologies, will present some of the key findings of utilizing MSC-based treatments on Spinocerebellar Ataxia (SCA) and Acute Liver Failures (ALF), both are debilitating medical needs without effective options.


Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com